Consensus estimates project Q2 2026 revenue of $393.4 million and an EPS loss of $0.69, while the current stock price of $101.49 remains well below the average analyst price target of $211.25.
Investors are primarily focused on the commercial sales trajectory of BRINSUPRI (brensocatib) as it ramps up following its blockbuster-potential launch in the bronchiectasis market.
Management has targeted at least $1 billion in annual BRINSUPRI revenue for 2026, making this quarter's performance a critical indicator of the drug's long-term growth potential. Additionally, shareholders are watching for pipeline updates on the Phase 3 PALM-PAH study of TPIP and commentary on the company's path toward reaching cash flow positivity in 2027.